Update on the Pathogenesis, Diagnosis, and Therapy of AIDS-related Lymphoma

Overview

Journal Curr Infect Dis Rep

Specialty Infectious Diseases

Date 2003 Mar 19

PMID 12642005

Citations 1

Authors

Richard F Little

Wyndham H Wilson

Affiliations

Soon will be listed here.

Abstract

AIDS-related non-Hodgkin's lymphoma (ARL) is an opportunistic malignancy that foreshortens life more than any other commonly occurring HIV-associated cancer. Treatment strategies include low-dose chemotherapy, chemotherapy given with antiretroviral therapy, and infusional chemotherapy regimens. Rituximab, an anti-CD20 monoclonal antibody, has been found to be useful in non-HIV-associated lymphomas and is of interest in ARL as well. Since the advent of highly active antiretroviral therapy, the ARL incidence and survival has changed. This paper reviews the epidemiologic, biologic, and clinical features of ARL with the aim of presenting a cohesive overview of these elements.

Citing Articles

How I treat HIV-associated lymphoma.

Dunleavy K, Wilson W Blood. 2012; 119(14):3245-55.

PMID: 22337719 PMC: 3321851. DOI: 10.1182/blood-2011-08-373738.

References

Spina M, Vaccher E, Juzbasic S, Milan I, Nasti G, Talamini R . Human immunodeficiency virus-related non-Hodgkin lymphoma: activity of infusional cyclophosphamide, doxorubicin, and etoposide as second-line chemotherapy in 40 patients. Cancer. 2001; 92(1):200-6. DOI: 10.1002/1097-0142(20010701)92:1<200::aid-cncr1310>3.0.co;2-a. View

Carbone A, Gloghini A, Larocca L, Capello D, Pierconti F, Canzonieri V . Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood. 2001; 97(3):744-51. DOI: 10.1182/blood.v97.3.744. View

Levine A, Sullivan-Halley J, Pike M, Rarick M, Loureiro C, WILLSON E . Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival. Cancer. 1991; 68(11):2466-72. DOI: 10.1002/1097-0142(19911201)68:11<2466::aid-cncr2820681124>3.0.co;2-g. View

Gascoyne R, Adomat S, Krajewski S, Krajewska M, Horsman D, Tolcher A . Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood. 1997; 90(1):244-51. View

Miller T, Grogan T, Dahlberg S, Spier C, Braziel R, Banks P . Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood. 1994; 83(6):1460-6. View

Gaidano G, Pastore C, Lanza C, Mazza U, Saglio G . Molecular pathology of AIDS-related lymphomas. Biologic aspects and clinicopathologic heterogeneity. Ann Hematol. 1994; 69(6):281-90. DOI: 10.1007/BF01696556. View

Kaplan L, Straus D, Testa M, Von Roenn J, Dezube B, Cooley T . Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997; 336(23):1641-8. DOI: 10.1056/NEJM199706053362304. View

Sparano J, Wiernik P, Strack M, Leaf A, BECKER N, Sarta C . Infusional cyclophosphamide, doxorubicin and etoposide in HIV-related non-Hodgkin's lymphoma: a follow-up report of a highly active regimen. Leuk Lymphoma. 1994; 14(3-4):263-71. DOI: 10.3109/10428199409049677. View

Kamel O, van de Rijn M, Weiss L, Del Zoppo G, Hench P, Robbins B . Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med. 1993; 328(18):1317-21. DOI: 10.1056/NEJM199305063281806. View

10.

Wilson W, Teruya-Feldstein J, Fest T, Harris C, Steinberg S, Jaffe E . Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood. 1997; 89(2):601-9. View

11.

Nador R, Cesarman E, Chadburn A, Dawson D, Ansari M, Sald J . Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood. 1996; 88(2):645-56. View

12.

Raez L, Patel P, Feun L, Restrepo A, Raub Jr W, Cassileth P . Natural history and prognostic factors for survival in patients with acquired immune deficiency syndrome (AIDS)-related primary central nervous system lymphoma (PCNSL). Crit Rev Oncog. 1999; 9(3-4):199-208. View

13.

Ballerini P, Gaidano G, Gong J, Tassi V, Saglio G, Knowles D . Molecular pathogenesis of HIV-associated lymphomas. AIDS Res Hum Retroviruses. 1992; 8(5):731-5. View

14.

. Revision of the case definition of acquired immunodeficiency syndrome for national reporting--United States. MMWR Morb Mortal Wkly Rep. 1985; 34(25):373-5. View

15.

Alizadeh A, Eisen M, Davis R, Ma C, Lossos I, Rosenwald A . Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-11. DOI: 10.1038/35000501. View

16.

Rosenwald A, Wright G, Chan W, Connors J, Campo E, Fisher R . The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346(25):1937-47. DOI: 10.1056/NEJMoa012914. View

17.

Mackall C, Fleisher T, Brown M, Magrath I, Shad A, Horowitz M . Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood. 1994; 84(7):2221-8. View

18.

Liu Z, Savoldo B, Huls H, Lopez T, Gee A, Wilson J . Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas. Recent Results Cancer Res. 2002; 159:123-33. DOI: 10.1007/978-3-642-56352-2_15. View

19.

Karp J, Broder S . The pathogenesis of AIDS lymphomas: a foundation for addressing the challenges of therapy and prevention. Leuk Lymphoma. 1992; 8(3):167-88. DOI: 10.3109/10428199209054903. View

20.

Levine A . Epidemiology, clinical characteristics, and management of AIDS-related lymphoma. Hematol Oncol Clin North Am. 1991; 5(2):331-42. View